Expression of secretory phospholipase A2s in human atherosclerosis development.
Secretory phospholipase A2s (sPLA2s) contribute to the hydrolysis of phospholipid. Among them, sPLA2-IIA, -V, and -X have been regarded as enhancers of lipid accumulation in arterial intima. However, the distribution and production of the other types of sPLA2 in human aortic wall remain unclear. Therefore, in this study, the distribution and production of seven types of sPLA2 including IIA, IID, IIE, IIF, III, V, and X in atherosclerosis development in the human aorta were comprehensively examined by immunohistochemistry and in situ hybridization (ISH). The extent of sPLA2s expression increased with atherosclerosis development, but only sPLA2-IIF was never observed in the normal aorta. Double-immunostaining demonstrated that sPLA2-V expression was limited to smooth muscle cells (SMCs), although the other sPLA2s were expressed in both macrophages and SMCs. ISH using sPLA2 cDNAs revealed that the expression pattern of each mRNA was consistent with the results of immunohistochemistry for each corresponding sPLA2. These results indicate that the seven types of sPLA2 are expressed with various patterns in all stages of atherosclerosis development and may play an atherogenic role through degradation of phospholipid.
Kimura-Matsumoto
Masayo
M
Department of Pathology, Toho University, School of Medicine, 5-21-16 Ohmori-nishi, Ohta-ku, Tokyo 143-8540, Japan. Electronic address: m-kimura@med.toho-u.ac.jp.
Ishikawa
Yukio
Y
Department of Pathology, Toho University, School of Medicine, 5-21-16 Ohmori-nishi, Ohta-ku, Tokyo 143-8540, Japan.
Komiyama
Kazuo
K
Nihon University, School of Dentistry, Tokyo, Japan.
Tsuruta
Tadashi
T
Nihon University, School of Dentistry, Tokyo, Japan.
Murakami
Makoto
M
Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; Department of Health Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan; Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama, Japan.
Masuda
Seiko
S
Department of Health Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan.
Akasaka
Yoshikiyo
Y
Department of Pathology, Toho University, School of Medicine, 5-21-16 Ohmori-nishi, Ohta-ku, Tokyo 143-8540, Japan.
Ito
Kinji
K
Department of Pathology, Toho University, School of Medicine, 5-21-16 Ohmori-nishi, Ohta-ku, Tokyo 143-8540, Japan.
Ishiguro
Shigeki
S
Department of Pathology, Toho University, School of Medicine, 5-21-16 Ohmori-nishi, Ohta-ku, Tokyo 143-8540, Japan.
Morita
Hiroshi
H
Department of Gastroenterology and Hepatology, Toho University Ohmori Medical Center, Tokyo, Japan.
Sato
Shinji
S
Department of Gastroenterology and Hepatology, Toho University Ohmori Medical Center, Tokyo, Japan.
Ishii
Toshiharu
T
Department of Pathology, Toho University, School of Medicine, 5-21-16 Ohmori-nishi, Ohta-ku, Tokyo 143-8540, Japan.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001012:Aorta, Abdominal / Q000378:metabolism; D001013:Aorta, Thoracic / Q000378:metabolism; D050197:Atherosclerosis / Q000201:enzymology* / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D032389:Myocytes, Smooth Muscle / Q000378:metabolism*; D054497:Phospholipases A2, Secretory / Q000378:metabolism*
D054497:Phospholipases A2, Secretory